ETON PHARMACEUTICALS ($ETON) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of $0.07 per share, beating estimates of $0.05 by $0.02. The company also reported revenue of $17,280,000, beating estimates of $15,433,620 by $1,846,380.
You can see Quiver Quantitative's $ETON stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ETON PHARMACEUTICALS Hedge Fund Activity
We have seen 53 institutional investors add shares of ETON PHARMACEUTICALS stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 1,263,528 shares (+223.2%) to their portfolio in Q4 2024, for an estimated $16,830,192
- CANNELL CAPITAL LLC added 381,323 shares (+inf%) to their portfolio in Q4 2024, for an estimated $5,079,222
- ACUITAS INVESTMENTS, LLC removed 185,824 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,411,995
- ACADIAN ASSET MANAGEMENT LLC added 142,551 shares (+134.5%) to their portfolio in Q4 2024, for an estimated $1,898,779
- MILLENNIUM MANAGEMENT LLC added 138,887 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,849,974
- NANTAHALA CAPITAL MANAGEMENT, LLC added 119,750 shares (+12.0%) to their portfolio in Q4 2024, for an estimated $1,595,070
- UBS GROUP AG added 116,335 shares (+611.7%) to their portfolio in Q4 2024, for an estimated $1,549,582
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ETON PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ETON in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley issued a "Buy" rating on 01/10/2025
- Craig-Hallum issued a "Buy" rating on 01/08/2025
To track analyst ratings and price targets for ETON PHARMACEUTICALS, check out Quiver Quantitative's $ETON forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
